OA13365A - Substituted quinoline compounds. - Google Patents
Substituted quinoline compounds. Download PDFInfo
- Publication number
- OA13365A OA13365A OA1200600247A OA1200600247A OA13365A OA 13365 A OA13365 A OA 13365A OA 1200600247 A OA1200600247 A OA 1200600247A OA 1200600247 A OA1200600247 A OA 1200600247A OA 13365 A OA13365 A OA 13365A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- group
- phenyl
- halo
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54167804P | 2004-02-04 | 2004-02-04 | |
| US63376304P | 2004-12-06 | 2004-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA13365A true OA13365A (en) | 2007-04-13 |
Family
ID=34890449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200600247A OA13365A (en) | 2004-02-04 | 2005-01-24 | Substituted quinoline compounds. |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7468378B2 (fr) |
| EP (1) | EP1716137A1 (fr) |
| JP (1) | JP2007520543A (fr) |
| KR (1) | KR100799802B1 (fr) |
| AP (1) | AP2006003685A0 (fr) |
| AR (1) | AR047529A1 (fr) |
| AU (1) | AU2005214159A1 (fr) |
| BR (1) | BRPI0507462A (fr) |
| CA (1) | CA2555133A1 (fr) |
| CO (1) | CO5700721A2 (fr) |
| CR (1) | CR8544A (fr) |
| EA (1) | EA010369B1 (fr) |
| EC (1) | ECSP066717A (fr) |
| GE (1) | GEP20084360B (fr) |
| IL (2) | IL176715A0 (fr) |
| MA (1) | MA28347A1 (fr) |
| NL (1) | NL1028192C2 (fr) |
| NO (1) | NO20063928L (fr) |
| OA (1) | OA13365A (fr) |
| PA (1) | PA8623001A1 (fr) |
| PE (1) | PE20050773A1 (fr) |
| SV (1) | SV2007002007A (fr) |
| TW (2) | TWI306454B (fr) |
| UY (1) | UY28734A1 (fr) |
| WO (1) | WO2005080373A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| AP2006003685A0 (en) * | 2004-02-04 | 2006-08-31 | Pfizer Prod Inc | Substituted quinoline compounds |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| EP1740553A1 (fr) * | 2004-04-14 | 2007-01-10 | AstraZeneca AB | Derives d'aryle glycinamide et utilisation en tant qu'antagonistes de nk1 et en tant qu'inhibiteurs du recaptage de serotonine |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| WO2006113910A2 (fr) | 2005-04-19 | 2006-10-26 | Surface Logix, Inc. | Inhibiteurs des secretions microsomales des apo-b et des proteines de transfert des triglycerides |
| WO2008050199A2 (fr) * | 2006-10-23 | 2008-05-02 | Pfizer Japan Inc. | Composés de phénylméthyl bicyclocarboxyamide substitués |
| KR20090064478A (ko) | 2006-11-13 | 2009-06-18 | 화이자 프로덕츠 인크. | 디아릴, 디피리디닐 및 아릴-피리디닐 유도체, 및 이들의 용도 |
| EP2115368A1 (fr) * | 2007-02-02 | 2009-11-11 | Steve D. Shivvers | Dispositif de séchage à haut rendement équipé de zones de chauffage et de séchage à plusieurs étages |
| WO2008100423A1 (fr) * | 2007-02-09 | 2008-08-21 | Sirtris Pharmaceuticals, Inc. | Inhibiteurs de protéines microsomiques de transport des triglycérides de l'intestin |
| WO2009014674A1 (fr) * | 2007-07-23 | 2009-01-29 | Sirtris Pharmaceuticals, Inc. | Hétérocyclylamides comme inhibiteurs de la protéine de transport de triglycérides microsomal de l'intestin |
| EP2214481B1 (fr) | 2007-10-15 | 2019-05-01 | United Animal Health, Inc. | Procédé permettant d'accroître la performance d'une progéniture |
| EP3797775A1 (fr) | 2007-10-19 | 2021-03-31 | Novartis AG | Compositions et procédés pour le traitement de la rétinopathie diabétique |
| WO2010018547A1 (fr) * | 2008-08-13 | 2010-02-18 | Pfizer Inc. | Composés aminoquinoline |
| MX2013015274A (es) | 2011-06-24 | 2014-03-31 | Amgen Inc | Anatagonista trpm8 y su uso en tratamientos. |
| JP2014517074A (ja) | 2011-06-24 | 2014-07-17 | アムジエン・インコーポレーテツド | Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用 |
| CN103958502B (zh) * | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | 作为丝氨酸/苏氨酸激酶抑制剂的喹唑啉化合物 |
| US8952009B2 (en) | 2012-08-06 | 2015-02-10 | Amgen Inc. | Chroman derivatives as TRPM8 inhibitors |
| EP3107540A4 (fr) * | 2014-02-17 | 2017-08-30 | Hetero Research Foundation | Polymorphes de lomitapide et ses sels |
| EP3798214B1 (fr) | 2014-10-06 | 2022-09-14 | Vertex Pharmaceuticals Incorporated | Modulateurs de régulateur de conductance transmembranaire de la fibrose kystique |
| US10138206B2 (en) | 2014-10-09 | 2018-11-27 | Glenmark Pharmaceuticals Limited | Amorphous form of lomitapide mesylate |
| CA3019380A1 (fr) | 2016-03-31 | 2017-10-05 | Vertex Pharmaceuticals Incorporated | Modulateurs du regulateur de la conductance transmembranaire de la fibrose kystique |
| ES2900263T3 (es) | 2016-09-30 | 2022-03-16 | Vertex Pharma | Modulador de regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de fabricación del modulador |
| JOP20190125B1 (ar) | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| CA3066084A1 (fr) | 2017-06-08 | 2018-12-13 | Vertex Pharmaceuticals Incorporated | Methodes de traitement de la fibrose kystique |
| EP3654969A1 (fr) | 2017-07-17 | 2020-05-27 | Vertex Pharmaceuticals Incorporated | Méthodes de traitement de la fibrose kystique |
| TWI799435B (zh) | 2017-08-02 | 2023-04-21 | 美商維泰克斯製藥公司 | 製備化合物之製程 |
| CA3078893A1 (fr) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | Formes cristallines et compositions de modulateurs de cftr |
| EP3720849A2 (fr) | 2017-12-08 | 2020-10-14 | Vertex Pharmaceuticals Incorporated | Procédés pour préparer des modulateurs du régulateur de la conductance transmembranaire de la mucoviscidose |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| EP3774825A1 (fr) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulateurs du régulateur de la conductance transmembranaire de la fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2819039A1 (de) | 1978-04-29 | 1979-11-08 | Bayer Ag | Leimungsmittel fuer papier |
| AU558909B2 (en) | 1981-03-11 | 1987-02-12 | Wellcome Foundation Limited, The | Biphenyl compounds |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| CA2091102C (fr) | 1992-03-06 | 2009-05-26 | John R. Ii Wetterau | Proteine de transfert de triglycerides microsomaux |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| CZ291476B6 (cs) | 1994-05-27 | 2003-03-12 | Smithkline Beecham S. P. A. | N-(alfa-Ethylbenzyl)-3-hydroxy-2-fenylchinolin-4-karboxamid, farmaceutický prostředek s jeho obsahem a použití |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| DE19519245C2 (de) * | 1995-04-14 | 2003-04-30 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DK0832069T3 (da) | 1995-06-07 | 2003-04-22 | Pfizer | Biphenyl-2-carboxylsyre-tetrahydroisoquinolin-6-ylamidderivater, deres fremstilling og deres anvendelse som inhibitorer af sekretion af mikrosomalt triglyceridoverførselsprotein og/eller apolipoprotein B (Apo B) |
| WO1996040640A1 (fr) | 1995-06-07 | 1996-12-19 | Pfizer Inc. | DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B) |
| US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| SK283162B6 (sk) * | 1996-05-20 | 2003-03-04 | Darwin Discovery Limited | Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom |
| JP2000515501A (ja) | 1996-07-01 | 2000-11-21 | イーライ・リリー・アンド・カンパニー | 低血糖化および低脂血化用化合物群 |
| KR100217618B1 (ko) * | 1996-12-12 | 1999-09-01 | 정몽규 | 와셔액 분사위치 조절 장치 |
| WO1998027979A1 (fr) | 1996-12-20 | 1998-07-02 | Bristol-Myers Squibb Company | Inhibiteurs heterocycliques de la proteine de transfert des triglycerides microsomiques et methode associee |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US5968950A (en) | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| ES2287971T3 (es) | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| AP1201A (en) | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
| CA2309882A1 (fr) * | 1997-12-22 | 1999-07-01 | Pharmacia & Upjohn Company | 4-hydroxyquinoline-3-carboxamides et hydrazides utilises comme agents antiviraux |
| CO5090829A1 (es) | 1998-07-21 | 2001-10-30 | Novartis Ag | Compuestos organicos de la formula i, utiles como inhibido res de la proteina de transferencia de triglicerido microso mal y de la secrecion de la apolipoproteina b. |
| CA2325358C (fr) | 1999-11-10 | 2005-08-02 | Pfizer Products Inc. | Amides de l'acide 7-¬(4'-trifluoromethylbiphenyl-2-carbonyl)amino|-quinoleine-3-carboxylique et methodes pour inhiber la secretion d'apolipoproteine b |
| IL139449A0 (en) | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Use of apo b secretion/mtp inhibitors |
| US20020032238A1 (en) * | 2000-07-08 | 2002-03-14 | Henning Priepke | Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments |
| US6417367B1 (en) * | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
| JP2004510763A (ja) | 2000-10-05 | 2004-04-08 | 藤沢薬品工業株式会社 | アポｂ分泌阻害剤としてのベンズアミド化合物 |
| OA12626A (en) | 2001-06-28 | 2006-06-13 | Pfizer Prod Inc | triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP)and/or apolipoprotein B(APO B) secretion. |
| EP1447402A4 (fr) * | 2001-10-25 | 2005-01-19 | Compose quinoline | |
| AU2002360489A1 (en) * | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| US20030162788A1 (en) * | 2002-01-10 | 2003-08-28 | Boehringer Ingelheim Pharma Kg | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals |
| US7625948B2 (en) | 2002-02-28 | 2009-12-01 | Japan Tobacco Inc. | Ester compound and medicinal use thereof |
| JP2006516028A (ja) * | 2002-12-20 | 2006-06-15 | ファイザー・プロダクツ・インク | ミクロソームトリグリセリド輸送タンパク質阻害剤 |
| WO2004056777A1 (fr) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Inhibiteurs de proteine microsomale de transfert de triglyceride |
| AP2006003685A0 (en) * | 2004-02-04 | 2006-08-31 | Pfizer Prod Inc | Substituted quinoline compounds |
-
2005
- 2005-01-24 AP AP2006003685A patent/AP2006003685A0/xx unknown
- 2005-01-24 EA EA200601239A patent/EA010369B1/ru not_active IP Right Cessation
- 2005-01-24 AU AU2005214159A patent/AU2005214159A1/en not_active Abandoned
- 2005-01-24 WO PCT/IB2005/000167 patent/WO2005080373A1/fr active Application Filing
- 2005-01-24 KR KR1020067015770A patent/KR100799802B1/ko not_active IP Right Cessation
- 2005-01-24 CA CA002555133A patent/CA2555133A1/fr not_active Abandoned
- 2005-01-24 OA OA1200600247A patent/OA13365A/en unknown
- 2005-01-24 BR BRPI0507462-2A patent/BRPI0507462A/pt not_active IP Right Cessation
- 2005-01-24 JP JP2006551942A patent/JP2007520543A/ja active Pending
- 2005-01-24 EP EP05702327A patent/EP1716137A1/fr not_active Withdrawn
- 2005-01-24 GE GEAP20059563A patent/GEP20084360B/en unknown
- 2005-02-02 PE PE2005000125A patent/PE20050773A1/es not_active Application Discontinuation
- 2005-02-02 UY UY28734A patent/UY28734A1/es unknown
- 2005-02-02 AR ARP050100394A patent/AR047529A1/es not_active Application Discontinuation
- 2005-02-03 TW TW094103301A patent/TWI306454B/zh not_active IP Right Cessation
- 2005-02-03 TW TW097141214A patent/TW200906800A/zh unknown
- 2005-02-03 US US11/049,852 patent/US7468378B2/en not_active Expired - Fee Related
- 2005-02-04 SV SV2005002007A patent/SV2007002007A/es not_active Application Discontinuation
- 2005-02-04 NL NL1028192A patent/NL1028192C2/nl not_active IP Right Cessation
- 2005-02-04 PA PA20058623001A patent/PA8623001A1/es unknown
-
2006
- 2006-06-15 US US11/424,488 patent/US7368573B2/en not_active Expired - Fee Related
- 2006-07-05 IL IL176715A patent/IL176715A0/en unknown
- 2006-07-21 EC EC2006006717A patent/ECSP066717A/es unknown
- 2006-07-28 CO CO06074303A patent/CO5700721A2/es not_active Application Discontinuation
- 2006-08-03 CR CR8544A patent/CR8544A/es not_active Application Discontinuation
- 2006-08-04 MA MA29241A patent/MA28347A1/fr unknown
- 2006-09-01 NO NO20063928A patent/NO20063928L/no not_active Application Discontinuation
- 2006-10-30 US US11/554,351 patent/US7393958B2/en not_active Expired - Fee Related
-
2010
- 2010-10-27 IL IL208963A patent/IL208963A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA13365A (en) | Substituted quinoline compounds. | |
| AP1388A (en) | Nicotinamide derivatives | |
| KR100575919B1 (ko) | 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜 | |
| MXPA02009020A (es) | Derivados de beta-aminoacidos ciclicos como inhibidores de las metaloproteasas de matriz y factor de necrosis de tumor alfa. | |
| EP1883630A2 (fr) | Procedes de synthese de derives de 6-alkylaminoquinoline | |
| JP2001504809A (ja) | マトリクス金属プロテナイーゼおよびｔａｃｅに対する阻害薬としてのオルト―スルホンアミドアリールヒドロキサム酸の製造および使用 | |
| BRPI0809931B1 (pt) | antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo | |
| EP2141147A1 (fr) | Dérivé de l'ornithine | |
| JP2006514032A (ja) | ミクロソームトリグリセリド転送タンパク質阻害剤 | |
| WO2004056775A1 (fr) | Inhibiteurs de proteine de transfert de triglyceride microsomale | |
| JPH11500436A (ja) | １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途 | |
| MXPA06007785A (en) | Substituted quinoline compounds | |
| JPH05239024A (ja) | 縮合複素環カルボン酸誘導体、その製造法、中間体および剤 | |
| US20130072519A1 (en) | 2-phenyl benzoylamides |